CONCLUSIONS: Robot-assisted radical nephrectomy with IVC tumor thrombectomy for Level I-II tumor thrombi produced shorter hospitalization, less requirement for transfusion, and less frequent complications compared to the open approach. On early follow up, there is no difference in survival, but longer follow up is required to validate long term oncological outcomes.
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MP37-18 ONCOLOGIC OUTCOMES AFTER ROBOT-ASSISTED RADICAL NEPHROURETERECTOMY FOR UPPER URINARY TRACT MALIGNANCY
INTRODUCTION AND OBJECTIVES:
While open nephroureterectomy for upper urinary tract carcinoma is accepted as oncologically sound, a scarcity of data exists regarding oncologic outcomes after robot-assisted radical nephroureterectomy (RARNU). We present outcomes from a large series of patients undergoing RARNU.
METHODS: The City of Hope nephroureterectomy database was used to identify patients who underwent RARNU between February 2005 and March 2018. Exclusion criteria included previous or concurrent muscle-invasive bladder cancer, non-upper urinary tract primary malignancy, concurrent additional surgery, and conversion to open surgery. 73 cases were identified. Demographic, pathologic, and outcomes data were collected. The reverse Kaplan-Meier method was used to calculate urothelial recurrence-free (URFS), metastasis-free (MFS), urothelial recurrence-or metastasis-free (RMFS), and overall survival (OS). Univariate and multivariate analysis was performed to identify predictors of these endpoints.
RESULTS: Median age was 68 years. 42/73 (57.5%) of patients were male. Median BMI was 25.9 kg/m 2 . 4 (5.5%) patients had a history of prior or concurrent non-invasive bladder cancer. 24/73 (32.9%) of patients had pT3-4 disease. 5/73 (6.8%) patients had variant histology, 8/73 (11.0%) had carcinoma in situ, and 9/73 (12.3%) had lymphovascular invasion on final pathology. Median lymph node yield was 9 (IQR 6-15). 8/73 patients (11.0%) had positive margins. Urothelial recurrences occurred in 25/73 patients (34.2%). Of these patients, 24 had a recurrence in the bladder. 23/73 (31.5%) patients developed metastases at a mean of 11.8 months. Of these patients, 18 had metastases outside the retroperitoneum. There were no cases Vol. 201, No. 4S, Supplement, Saturday, May 4, 2019 THE JOURNAL OF UROLOGY Ò e531
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